Keyphrases
Gliclazide
100%
Omeprazole
100%
CYP2C19 Polymorphism
100%
Hypoglycemia
30%
Type 2 Diabetic Patients
20%
Area under the Curve
20%
CYP2C19
20%
Physiologically-based Pharmacokinetic Model
20%
Scotland
10%
Modeling Approach
10%
Clinical Trials
10%
Healthy Volunteers
10%
Metabolism
10%
Antidiabetic Drugs
10%
Days of Treatment
10%
Twice Daily
10%
Once-daily
10%
Pharmacokinetic Profile
10%
Poor Metabolizer
10%
Human Pharmacokinetics
10%
In Vivo Pharmacokinetics
10%
Co-treatment
10%
Pharmacokinetic Simulation
10%
Intermediate Metabolizers
10%
Ultrarapid Metabolizer
10%
Pharmacology, Toxicology and Pharmaceutical Science
Gliclazide
100%
CYP2C19
100%
Omeprazole
100%
Hypoglycemia
30%
Pharmacokinetics
30%
Non Insulin Dependent Diabetes Mellitus
20%
Clinical Trial
10%
Antidiabetic Agent
10%
Normal Human
10%
Physiologically Based Pharmacokinetic Modelling
10%
Immunology and Microbiology
Pharmacokinetics
100%
Normal Human
25%